14-day Premium Trial Subscription Try For FreeTry Free

CytomX Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 71.54. In total, the insiders bought 4 082 793 and sold 424 279 CTMX shares in the last 100 trades.

Insider Power

(Last 100 transactions)
71.54
Buy 4 082 793 Shares
Sell 424 279 Shares

Historical Insider Trades

Date Type Action Person Amount
Aug 20, 2024 Common Stock Buy Landau Jeffrey B 11 250
Aug 20, 2024 Common Stock Sell Landau Jeffrey B 4 181
Aug 20, 2024 Performance Stock Units (PSUs) Sell Landau Jeffrey B 11 250
Aug 20, 2024 Common Stock Buy Belvin Marcia 11 250
Aug 20, 2024 Common Stock Sell Belvin Marcia 4 181
Aug 20, 2024 Performance Stock Units (PSUs) Sell Belvin Marcia 11 250
Aug 20, 2024 Common Stock Buy Rowland Lloyd A 11 250
Aug 20, 2024 Common Stock Sell Rowland Lloyd A 4 181
Aug 20, 2024 Performance Stock Units (PSUs) Sell Rowland Lloyd A 11 250
Aug 20, 2024 Common Stock Buy Ogden Christopher 6 875
Aug 20, 2024 Common Stock Sell Ogden Christopher 1 984
Aug 20, 2024 Performance Stock Units (PSUs) Sell Ogden Christopher 6 875
Aug 20, 2024 Common Stock Buy Mccarthy Sean A. 37 500
Aug 20, 2024 Common Stock Sell Mccarthy Sean A. 13 898
Aug 20, 2024 Performance Stock Units (PSUs) Sell Mccarthy Sean A. 37 500
Jun 12, 2024 Common Stock Buy Ogden Christopher 17 500
Jun 12, 2024 Stock Option (Right to Buy) Buy Ogden Christopher 75 000
May 15, 2024 Stock Option (Right to Buy) Buy Young Matthew P. 38 000
May 15, 2024 Stock Option (Right to Buy) Buy Su Zhen 38 000
May 15, 2024 Stock Option (Right to Buy) Buy Mohindru Mani 38 000
May 15, 2024 Stock Option (Right to Buy) Buy Meyers James R 38 000
May 15, 2024 Stock Option (Right to Buy) Buy Jones Elaine V 38 000
May 15, 2024 Stock Option (Right to Buy) Buy Gilbert Halley E 38 000
May 15, 2024 Stock Option (Right to Buy) Buy Ashworth Alan 38 000
Mar 26, 2024 Common Stock Buy Mccarthy Sean A. 109 768
Click to get the best stock tips daily for free!
ABOUT CYTOMX THERAPEUTICS
CytomX Therapeutics
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...
GOLDEN STAR
Ticker Change Signal Date
WM
$207.93
0.558% Oct 01
VET
$9.77
7.06% Sep 30
FSK
$19.73
1.57% Sep 30
XOM
$115.82
5.84% Sep 27
HES
$133.61
5.43% Sep 27

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE